Skip to the beginning of the images gallery

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector Updated Research Available

Value Chain Expansion to Support Next generation Biologics Drives Future Growth Potential

INDUSTRY
Healthcare

SECTOR
Life Sciences

RELEASE DATE
10-May-2023

REGION
Global

DELIVERABLE TYPE
Market Research

RESEARCH CODE
PDEF-01-00-00-00

SKU
HC03664-GL-MT_27657

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector
Published on: 10-May-2023 | SKU: HC03664-GL-MT_27657

Need more details?

$4,950.00

$3,712.50 save 25 %

DownloadLink

Link1 sample $0.00

Qty

Request Sample

Need more details?

Description

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market
and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe;
and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional
fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and
manufacturing and packaging services, into one integrated process (from drug development through manufacturing).

The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability
and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs—from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency.

Author: Surbhi Gupta

Infographic

Table of Contents

Strategic Imperatives

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top Three Strategic Imperatives on the Global Biologics Contract Development and Manufacturing Organization (Bio-CDMO) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

Scope of Analysis

Market Segmentation by Product Type

Market Segmentation by Cell Expression System Type

Market Segmentation by Service Type

Key Regional Competitors in the Bio-CDMO Market

Growth Drivers

Growth Restraints

Growth Environment—Bio-CDMO Market

Biologics Pipeline Overview

Bio-CDMO Business Model—Value Chain Expansion

Overview of Key CDMO Activities to Support the Next-gen Biologics Modalities Driving Precision Medicine

Impact of Biosimilar Launches on CDMOs

Key Emerging Trends in the Bio-CDMO Industry

Key Emerging Trends in the Bio-CDMO Industry (continued)

New Modalities Paving the Way for New Entrants

New Modalities Paving Way for New Entrants

Product Distribution of Marketed Biologics in 2022

Distribution of Bioprocessing Technique—Single-use Bioreactors (SUB) and Fixed Multiuse Bioreactors (MUB) for Mammalian-based Manufacturing

Regional Distribution of Total Biomanufacturing Capacity

Growth Opportunity Analysis—Bio-CDMO Industry

Key Growth Metrics for the Global Bio-CDMO Market

Forecast Framework—Bio-CDMO Market Sizing

Forecast Methodology—Bio-CDMO Market

Forecast Assumptions and Considerations—Bio-CDMO Market

Revenue Forecast—Global Bio-CDMO Market

Revenue Forecast Analysis—Global Bio-CDMO Market

Revenue Forecast by Product Type

Revenue Forecast Analysis by Product Type

Revenue Forecast by Cell Expression System Type

Revenue Forecast Analysis for Mammalian Expression Systems

Revenue Forecast Analysis for Microbial Expression Systems

Revenue Forecast Analysis for Other Expression Systems

Revenue Split by Service Type

Competitive Environment

Revenue Share Estimation—Top Bio-CDMO Market Participants

Revenue Share Analysis—Top Bio-CDMO Market Participants

Growth Opportunity Universe

Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe

Growth Opportunity 1: Building CGT Manufacturing and Distribution Capabilities in Europe (continued)

Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia

Growth Opportunity 2: Improving and Expanding Viral Vector Manufacturing Capabilities in Asia (continued)

Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities

Growth Opportunity 3: Live Biotherapeutic Products (Microbiome) Manufacturing Capabilities (continued)

Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing

Growth Opportunity 4: Adoption of AI and Digital Twins in Biomanufacturing (continued)

Growth Opportunity 5: Discovery and Preclinical Services for New Modalities

Growth Opportunity 5: Discovery and Preclinical Services for New Modalities (continued)

Growth Opportunity 6: Purpose-built PAT Services for CGT

Growth Opportunity 6: Purpose-built PAT Services for CGT (continued)

Next Steps

Your Next Steps

Why Frost, Why Now?

List of Exhibits

Legal Disclaimer

Request Sample

Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Life Sciences research

13 Jan 2025 | Global | Market Outlook

Top 6 Growth Opportunities for the Digital Health Industry, 2025

Driven by digital advancements, the healthcare industry is transforming rapidly. Current trends and challenges create constant change, and industry stakeholders must adapt to remain attractive, competitive, and unique as robust organizations. Each year, competitors must gain a fresh, comprehensive v...

Cybersecurity in Healthcare, United States, 2024

Healthcare is the industry most affected by cyberattacks, which have targets like hospitals, healthcare organizations, patient databases, and connected devices. These attacks not only destabilize healthcare systems but also threaten care delivery and patient safety. The global healthcare infrastruct...

Top 6 Growth Opportunities for Clinical Diagnostics, Global, 2025

Accounting for 2%-3% of total healthcare expenditure and influencing 70% of clinical decision-making, diagnostics is the silent champion supporting all stages of precision health, including risk stratification, screening, early diagnosis, prognosis, monitoring, and relapse. The discovery and trans...

Frost Radar™: Enterprise Conversational AI in Healthcare, 2024

This Frost Radar™ benchmarks the companies and their solutions that allow healthcare payers and providers to create next-generation virtual assistants. Conversational AI is primarily used to streamline patient and provider processes and interactions across the care continuum—the pre-care, at-care, a...

Generative AI in Payer and Provider IT Transformation, Global, 2024-2029

The healthcare payer and provider industry is gradually adopting generative artificial intelligence (Gen AI) solutions across its value chain. Almost all organizations have shown an intent to implement Gen AI-based solutions in their products or processes, with a few already embarking on this journe...

Report download
Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:

Strategic Imperatives
Growth Opportunities
Best Practices
Companies to Action

Impacting your company's future growth potential.

Details

This research service provides an overview of the global biologics contract development and manufacturing organization (bio-CDMO) market and a 6-year market revenue forecast (2023 to 2028). The geographic scope covers three key regions, namely North America (NA); Europe; and Asia-Pacific (APAC). The report offers a detailed segment analysis of the bio-CDMO market, including emerging business models such as reserved capacity and contract research development and manufacturing organization (CRDMO) services that are set to dominate the traditional fee-for-service manufacturing services space. The market segments cover drug type (drug substance and drug products) and cell expression type (microbial, mammalian, and other modalities). The other modalities segment includes cell-free expression systems, such as nucleic acid-based products and insect- and plant-based expression systems. For the purpose of this study, the bio-CDMO market forecast includes services encompassing drug development and manufacturing processes, such as product development (R&D) services, analytical support, and manufacturing and packaging services, into one integrated process (from drug development through manufacturing). The industry shift toward biologics is boosting product pipelines and adoption, leading to more demand for biologics manufacturing capability and capacity expansion. Also, emerging biopharma companies hold two-thirds of the molecules in the R&D pipeline but have limited muscle to develop and commercialize these products. Bio-CDMOs can provide the agility and flexibility required for next-generation modalities such as CGT as they can use their modular facilities for multiple products and clients, which is a challenge for biopharma companies that build capabilities in-house. Big pharma is, therefore, increasingly choosing to outsource complex development and manufacturing processes and de-risking their supply chain instead of building more in-house manufacturing capacity. The transition of CDMOs to CRDMOs is leading them to offer end-to-end services. This positions competitors to partner with biopharmaceutical companies for their research, development, and manufacturing needs—from discovery to commercialization. While the COVID-19 pandemic has led to drug supply shortages, the pharmaceutical industry in general is moving toward right shoring, which involves keeping parts of the supply chain and processes in strategic locations to deliver the desired combination of cost and efficiency. CDMOs are playing a critical role in achieving supply chain resiliency. Author: Surbhi Gupta

More Information

More Information
Deliverable Type	Market Research
Author	Surbhi Gupta
Industries	Healthcare
No Index	No
Is Prebook	No
Keyword 1	biologics contract manufacturing
Keyword 2	Biologics CDMO Market
Keyword 3	biologics industry
Podcast	No
Predecessor	MG0C-01-00-00-00
WIP Number	PDEF-01-00-00-00

Growth Opportunities in the Biologics Contract Development and Manufacturing Organization Sector